How To Accelerate And Enhance ADC Therapies Using Payload Intermediates

Using payload intermediates can streamline the development and production of antibody-drug conjugates (ADCs), minimizing the complexity of drug synthesis, boosting process efficiency, improving product quality and safety, and supporting more cost-effective and efficient manufacturing. In this webinar, learn how payloads and advanced payload intermediates can expedite drug development and elevate ADC therapies. Explore ADC payloads like MMAE and Exatecan, as well as ADCore payload intermediates that offer quick access to highly sought-after ADC payload classes such as dolastatins, maytansinoids, and PBDs, alongside the solubility-enhancing ChetoSensar™ technology.